No Data
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Pfizer Price Target Lowered to $29 From $31 at UBS
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
Pfizer Options Spot-On: On January 7th, 183.88K Contracts Were Traded, With 3.21 Million Open Interest
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
